STOCK TITAN
  1. Home
  2. UROV

Urovant Sciences (UROV) Stock Price, News & Analysis

UROV NASDAQ
Published by Stock Titan Data refreshed

What Changed

Price Move History

Daily moves over 5%
28 253 sessions, March 26, 2020 to March 26, 2021
Largest daily move
+93.5% close of November 13, 2020
1-year change
+60% closing prices, March 26, 2020 to March 26, 2021

Company Description

UROV has gained 60.0% over the past year. The last closing price was $16.24.

This page collects what Stock Titan holds for UROV, including price data, latest news, SEC filings, insider trading activity, financial highlights, upcoming events, and short interest trends.

Stock Performance

Chart
$—
-
-
Last updated:
+60%
Performance 1 year
-
Market Cap
-
Shares outstanding

Urovant Sciences (UROV) closed at $16.24 on March 26, 2021. Over the past 12 months, the price has gained 60.0%.

See what a $1,000 investment in UROV would be worth today

UROV Metrics & Rankings

Month to date
+0.4%
View ranking
YTD
+0.7%
View ranking

Price returns through March 26, 2021. Month-to-date and YTD include the first trading day. Ranking links may use different dates.

Latest News

View All
—

Urovant Sciences to Present Interim Data from Phase 2a Study of Potential Novel Gene Therapy, URO-902, and New Analyses of Data from Phase 3 EMPOWUR Extension Trial of GEMTESA® (vibegron) 75 mg at 2022 American Urological Association Annual Meeting

conferences clinical trial
—

Urovant Sciences Announces Positive Topline Results of Phase 2a Trial of its Potential Novel Gene Therapy, URO-902

clinical trial
—

Urovant Sciences Announces Publication in Advances in Therapy of Analyses of Patient-Perceived Meaningfulness of Improvement in Symptom Reduction for Overactive Bladder Patients Treated with GEMTESA® (vibegron) 75 mg

—

Urovant Sciences Announces Publication in Blood Pressure Monitoring of Positive Ambulatory Blood Pressure Study Results for GEMTESA® (vibegron) 75 mg in Overactive Bladder Patients

0.00%

Urovant Sciences Provides Merger Update and Reports Third Quarter Fiscal Year 2020 Results

acquisition earnings
-0.12%

Urovant Sciences Announces Progression of URO-902 Phase 2a Trial Following Positive Recommendation from the Data and Safety Monitoring Board

clinical trial
0.00%

Urovant Sciences Announces U.S. FDA Approval of GEMTESA® (vibegron) 75 mg Tablets for the Treatment of Patients with Overactive Bladder (OAB)

fda approval
-0.62%

Urovant Sciences Announces Topline Data from Phase 2a Study of Vibegron for the Treatment of Irritable Bowel Syndrome (IBS) Pain Did Not Meet Primary Endpoint

clinical trial
+93.48%

Urovant Sciences Enters Into Definitive Agreement for Sumitovant Biopharma to Acquire All Outstanding Shares

acquisition
+93.48%

Sumitovant Biopharma and Urovant Sciences Announce Sumitovant's Acquisition of Remaining Stake in Urovant

acquisition

Urovant Sciences has 10 recent news articles. Of the recent coverage, 2 articles coincided with positive price movement and 2 with negative movement. Key topics include conferences, clinical trial, acquisition, earnings, fda approval. View all UROV news →

SEC Filings

View All

No SEC filings available for UROV.

Financial Highlights

—
Revenue (latest FY)
—
Net Income (latest FY)
—
Diluted EPS (latest FY)
—
Operating Cash Flow
—
Net Profit Margin
—
Oper. Profit Margin

Upcoming Events

Short Interest History

Last 12 Months

Days to Cover History

Last 12 Months

Frequently Asked Questions

What is the current quoted price of Urovant Sciences (UROV)?

The current quoted price of Urovant Sciences (UROV) is $16.24 as of March 26, 2021.